

## Changes to Emetic Risk of Chemotherapy Regimens in Adults

This table lists the regimens from the CCO Drug Formulary that had a change in emetic risk classification since the 2013 Antiemetic Report, and is not inclusive of all regimens.

### Breast

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CAPE+TRAS	Low	Minimal; No routine prophylaxis for capecitabine
CMF(PO)	Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO
CMF(PO)+TRAS	Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO
CRBPDOCETRAS	Moderate	Moderate + NK1 RA
FAC	Moderate	High

### Central Nervous System

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CRBPVNCR	Moderate (D1) / Minimal (D8, 15)	Moderate + NK1 RA (D1) / Minimal (D8, 15)
PCV	Moderate / Minimal	Minimal (D29); Consider prophylaxis daily for lomustine and procarbazine

### Gastrointestinal

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CAPE+BEVA	Low	Minimal; No routine prophylaxis for capecitabine
CAPECISP	High (Cisplatin) / Low (Capecitabine)	High: Cisplatin $\geq$ 70 or Moderate: Cisplatin <70 (D1); No routine prophylaxis for capecitabine
CAPECISP(RT)	Moderate	High; No routine prophylaxis for capecitabine
CAPECRBP	Moderate	Moderate + NK1 RA; No routine prophylaxis for capecitabine

This table is a summary of changes to the emetic risk category of regimens listed on the Drug Formulary website as at August 2018, and is not inclusive of all regimens. Refer to the Drug Formulary website for the most up-to-date regimen information, and to find the latest CCO Antiemetic Recommendations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

**Gastrointestinal (continued)**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CAPECRBP+TRAS	Moderate	Moderate + NK1 RA; No routine prophylaxis for capecitabine
CRBPFU	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPFU+TRAS	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
ECARBOF	Moderate / Minimal	Moderate + NK1 RA (D1) / Minimal (D2-21)
ECARBOX	Moderate / Low	Moderate + NK1 RA; No routine prophylaxis for capecitabine
EOF	High / Minimal	Moderate (D1)/ Minimal (D2-21)
EOX	High / Low	Moderate; No routine prophylaxis for capecitabine
FU(CIV)	Low	Minimal
RAMU	Low	Minimal

**Genitourinary**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CABO	Not available	Low - No routine prophylaxis
CRBPGEMCPACL	Moderate (D1) / Low (D8)	Moderate + NK1 RA (D1) / Low (D8)

**Gynecologic**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CRBP	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPDOCE	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPDOXO	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPPACL	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPPACL(IP)	Moderate	High
CRBPPACL(RT)	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)

This table is a summary of changes to the emetic risk category of regimens listed on the Drug Formulary website as at August 2018, and is not inclusive of all regimens. Refer to the Drug Formulary website for the most up-to-date regimen information, and to find the latest CCO Antiemetic Recommendations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

**Gynecologic (continued)**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CRBPPACL(W)	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPPACL+BEVA	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
CRBPPGLDX	Moderate	Moderate (+ NK1 RA for AUC ≥ 5)
DCTN	High	Moderate
EMA-CO	High (D1,2) / Moderate (D8)	Moderate
EP-EMA	High	High (D1) / Moderate (D8)

**Head and Neck**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CAPECRBP+CETU	Moderate (D1) / Low (D2-14) / Minimal (D15)	Moderate + NK1 RA (D1) / Minimal (D15); No routine prophylaxis for capecitabine
CRBP(RT-3W)	Moderate	Moderate + NK1 RA
CRBPFU+CETU	Moderate	Moderate + NK1 RA (D1) / Minimal (D8, 15)

**Hematologic**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CHLVPP	Moderate	Minimal; Consider prophylaxis daily for procarbazine PO
CVP(PO)	Moderate	Minimal; Consider prophylaxis daily for cyclophosphamide PO
CVP(PO)+R	Moderate	Minimal; Consider prophylaxis daily for cyclophosphamide PO
CYBORD	Low / Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO
CYBORP	Low / Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO

This table is a summary of changes to the emetic risk category of regimens listed on the Drug Formulary website as at August 2018, and is not inclusive of all regimens. Refer to the Drug Formulary website for the most up-to-date regimen information, and to find the latest CCO Antiemetic Recommendations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

**Hematologic (continued)**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CYCLDEXA+RITU	Moderate	Minimal; Consider prophylaxis daily for cyclophosphamide PO
CYCLETOP	Moderate	High (D1) / Low (D2-3)
CYTA	Low	Low (Minimal for SC)
CYTA(IT)	Low	Minimal
CYTAMTRX(IT)	Low	Minimal
DARA	Low	Minimal
DARADALENA	Low	Minimal; No routine prophylaxis for lenalidomide PO
DECI	Not available	Minimal
ESHAP	High	Moderate
FC(PO)+R	Moderate	Minimal; Consider prophylaxis daily for cyclophosphamide PO
FCM(PO)	Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO
FCM(PO)+R	Moderate	Low; Consider prophylaxis daily for cyclophosphamide PO
GDCRBP	Moderate (D1) / Low (D8)	Moderate + NK1 RA (D1) / Low (D8)
ICE	Moderate	Moderate + NK1 RA
PAD/VCD	Low (PAD) / Moderate (D1,8 VCD) / Low (D4, 11 VCD)	Low; Consider prophylaxis daily for cyclophosphamide PO
PRAL	Not available	Low

**Lung**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CISPVINO(W)	High / Minimal	Moderate (D1,8) / Minimal (D15,22)
CRBPETOP	Moderate	Moderate + NK1 RA

This table is a summary of changes to the emetic risk category of regimens listed on the Drug Formulary website as at August 2018, and is not inclusive of all regimens. Refer to the Drug Formulary website for the most up-to-date regimen information, and to find the latest CCO Antiemetic Recommendations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

**Lung (continued)**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CRBPETOP(PO)	Moderate/ Low	Moderate + NK1 RA; No routine prophylaxis for etoposide PO
CRBPETOP(RT)	Moderate	Moderate + NK1 RA
CRBPGEMC	Moderate (D1) / Low (D8)	Moderate + NK1 RA (D1) / Low (D8)
CRBPPEME	Moderate	Moderate + NK1 RA
CRBPPEME+BEVA	Moderate	Moderate + NK1 RA
CRBPPEME+PEMB	Moderate	Moderate + NK1 RA
CRBPRLT	Moderate	Moderate + NK1 RA
CRBPVINO	Moderate (D1) / Minimal (D8)	Moderate + NK1 RA (D1) / Minimal (D8)
CRBPVNBL(RT)	Moderate (D1, 29) / Minimal (D8, 15, 22)	Moderate + NK1 RA (D1, 29) / Minimal (D8, 15, 22)
DOX/DCTNVCR-CYCETOVCR	Not available	Minimal (Wk 2,3,5,6,8,9,11,12), Moderate (all other days)

**Sarcoma**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
DOXO	Moderate	Moderate < 60 mg /m <sup>2</sup> , High ≥ 60 mg /m <sup>2</sup>
IE-VAC	Moderate	Moderate (IE) / High (VAC)
MTRXVINO	Low	Minimal
MTRXVNBL	Low	Minimal
VActC	High	Moderate

This table is a summary of changes to the emetic risk category of regimens listed on the Drug Formulary website as at August 2018, and is not inclusive of all regimens. Refer to the Drug Formulary website for the most up-to-date regimen information, and to find the latest CCO Antiemetic Recommendations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

**Skin**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
ALDE(Intralesional)	Low	Minimal
TALI	Not available	Low

**Unknown Primary**

Regimen Name <sup>1</sup>	Old Emetic Risk Classification	New Emetic Risk Classification <sup>2</sup>
CRBPPAC+ETOP(PO)	Moderate/Low	Moderate + NK1 RA; No routine prophylaxis for etoposide PO

NK1 RA = neurokinin-1 receptor antagonist

<sup>1</sup> Regimens used across multiple disease sites are only listed here under the disease site with the highest usage. Refer to the CCO Drug Formulary for a full list of regimens by disease site.

<sup>2</sup> Regimens with both IV and oral components are classified based on the IV agents unless otherwise specified; refer to the “Emetic Risk of Single Oral Agents in Adults” table for emetic risk of oral agents alone.